-Frontline PESA, which is seen as an enabling law for tribal self-governance, is violated brazenly by both the Union government and State governments in the name of development. SINCE October 2012, the Ministry of Rural Development of the United Progressive Alliance (UPA) government has apparently been engaged in an exercise to evolve a "National Land Reforms Policy". Over these months, the Ministry wrote to various State governments, highlighting the importance of...

-PTI JOHANNESBURG: States may not prevent access to websites because they display opinions or beliefs that are critical of governments or established systems of thought, UN Human Rights Commissioner Navanethem "Navi" Pillay said here. Pillay, a South African of Indian Tamil origin, was delivering a lecture on 'Human Rights Achievements and Challenges in a Rapidly Changing World' at the University of the Witwatersrand as part of South Africa's celebration of Human Rights...

KEY TRENDS   • According to National Sample Survey report no. 583: Persons with Disabilities in India, the percentage of persons with disability who received aid/help from Government was 21.8 percent, 1.8 percent received aid/help from organisation other than Government and another 76.4 percent did not receive aid/ help *8   • As per National Family Health Survey-4 (NFHS-4), the Under-five Mortality Rate (U5MR) was 57.2 per 1,000 live births (for the non-STs it was 38.5)...

The recent Supreme Court judgment dismissing pharma giant Novartis’ claim for patent protections in India for its award-winning and prohibitively priced anti-leukemia drug Glivec has renewed the focus on accessibly-priced drugs – in particular the failure of the Indian public healthcare system and health policy to ensure affordable drugs for all. Studies show that as much as 70% of health spending in India comes from out-of-pocket payments, with 50-80% of...

-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's application covering a beta crystalline form of imatinib -the medicine Novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia (CML). The...